Ovarian cancer screening - Current status, future directions

Gynecologic Oncology

Volumn 132, Issue 2, 2014, Pages 490-495

  Menon, Usha ^a   Griffin, Michelle ^a   Gentry Maharaj, Aleksandra ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarkers; Imaging; Ovarian cancer; Screening; UKCTOCS

Indexed keywords

BIOMARKERS; IMAGING; OVARIAN CANCER; SCREENING; UKCTOCS;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84894028183     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.11.030     Document Type: Review

References (62)

1. P.E. Castle Gynecological cancer: more evidence supporting human papillomavirus testing Nat Rev Clin Oncol 9 2012 131 132
2. V.A. Moyer, and Force USPST Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement Ann Intern Med 157 2012 900 904
3. S.S. Buys, E. Partridge, and M.H. Greene et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screen of a randomized trial Am J Obstet Gynecol 193 2005 1630 1639
4. S.S. Buys, E. Partridge, and A. Black et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial JAMA 305 2011 2295 2303
5. P.F. Pinsky, A. Miller, and B.S. Kramer et al. Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Am J Epidemiol 165 2007 874 881
6. U. Menon, A. Gentry-Maharaj, and I. Jacobs Ovarian cancer screening and mortality JAMA 306 2011 1544 [author reply 1544-1545]
7. L.M. Baldwin, K.F. Trivers, and B. Matthews et al. Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med 156 2012 182 194
8. J.R. van Nagell Jr., P.D. DePriest, and F.R. Ueland et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened Cancer 109 2007 1887 1896
9. J.R. van Nagell Jr., R.W. Miller, and C.P. DeSimone et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening Obstet Gynecol 118 2011 1212 1221
10. I. Jacobs, and U. Menon Can ovarian cancer screening save lives? The question remains unanswered Obstet Gynecol 118 2011 1209 1211
11. M. Burnell, A. Gentry-Maharaj, and A. Ryan et al. Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials Trials 12 2011 61
12. H. Kobayashi, Y. Yamada, and T. Sado et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan Int J Gynecol Cancer 18 2008 414 420
13. S.J. Skates, F.J. Xu, and Y.H. Yu et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers Cancer 76 1995 2004 2010
14. U. Menon, A. Gentry-Maharaj, and R. Hallett et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Lancet Oncol 10 2009 327 340
15. I. Jacobs, A. Ryan, and S. Skates et al. Performance characteristics of multimodal screening with serum CA125 in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Presented at NCRI. Liverpool 2012
16. U. Menon, A. Ryan, and S. Campbell et al. Performance characteristics of ultrasound screening in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Presented at NCRI. Liverpool 2012
17. K.H. Lu, S. Skates, and M.A. Hernandez et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value Cancer 119 2013 3454 3461
18. B.B. Hermsen, R.I. Olivier, and R.H. Verheijen et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study Br J Cancer 96 2007 1335 1342
19. D. Stirling, D.G. Evans, and G. Pichert et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system J Clin Oncol 23 2005 5588 5596
20. A.N. Rosenthal, L. Fraser, and R. Manchanda et al. Results of annual screening in phase I of the United Kingdom Familial Ovarian Cancer Screening Study highlight the need for strict adherence to screening schedule J Clin Oncol 31 2013 49 57
21. A.N. Rosenthal, L. Fraser, and S. Philpott et al. Results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UK FOCSS Phase 2) Presented at American Society of Clinical Oncology. Chicago, IL 2013
22. S.J. Skates, P. Mai, and N.K. Horick et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status Cancer Prev Res (Phila) 4 2011 1401 1408
23. M.H. Greene, M. Piedmonte, and D. Alberts et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study Cancer Epidemiol Biomarkers Prev 17 2008 594 604
24. D.W. Cramer, R.C. Bast Jr., and C.D. Berg et al. Ovarian cancer biomarker performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial specimens Cancer Prev Res (Phila) 4 2011 365 374
25. M.A. Karlsen, N. Sandhu, and C. Hogdall et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass Gynecol Oncol 127 2012 379 383
26. L.E. Moore, R.M. Pfeiffer, and Z. Zhang et al. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial Cancer 118 2012 91 100
27. I. Jacobs, and U. Menon The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples Cancer Prev Res (Phila) 4 2011 299 302
28. E.P. Diamandis Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 102 2010 1462 1467
29. M.S. Pepe, Z. Feng, and H. Janes et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design J Natl Cancer Inst 100 2008 1432 1438
30. G.L. Anderson, M. McIntosh, and L. Wu et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study J Natl Cancer Inst 102 2010 26 38
31. J.F. Timms, U. Menon, and D. Devetyarov et al. Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks Cancer Genomics Proteomics 8 2011 289 305
32. C.K. Anderson, S. Wallace, and M. Guiahi et al. Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer Int J Gynecol Cancer 23 2013 417 421
33. M.W. Kamran, D. Vaughan, and D. Crosby et al. Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC) Eur J Obstet Gynecol Reprod Biol 170 2013 251 254
34. R.J. Kurman, and Ie M. Shih The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory Am J Surg Pathol 34 2010 433 443
35. L. Dubeau The cell of origin of ovarian epithelial tumours Lancet Oncol 9 2008 1191 1197
36. C.P. Crum, R. Drapkin, and A. Miron et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis Curr Opin Obstet Gynecol 19 2007 3 9
37. C.P. Crum, F.D. McKeon, and W. Xian The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention" Clin Obstet Gynecol 55 2012 24 35
38. D.W. Kindelberger, Y. Lee, and A. Miron et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship Am J Surg Pathol 31 2007 161 169
39. P.O. Brown, and C. Palmer The preclinical natural history of serous ovarian cancer: defining the target for early detection PLoS Med 6 2009 e1000114
40. S.S. Hori, and S.S. Gambhir Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations Sci Transl Med 3 2011 109ra116
41. M. Li, F. Diehl, and D. Dressman et al. BEAMing up for detection and quantification of rare sequence variants Nat Methods 3 2006 95 97
42. T. Forshew, M. Murtaza, and C. Parkinson et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA Sci Transl Med 4 2012 136ra168
43. I. Kinde, C. Bettegowda, and Y. Wang et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers Sci Transl Med 5 2013 167ra164
44. J.L. Xu, J. Commins, and E. Partridge et al. Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer Gynecol Oncol 125 2012 70 74
45. I.J. Jacobs, S. Skates, and A.P. Davies et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study BMJ 313 1996 1355 1358
46. U. Menon, S.J. Skates, and S. Lewis et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer J Clin Oncol 23 2005 7919 7926
47. S.J. Skates, U. Menon, and N. MacDonald et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women J Clin Oncol 21 2003 206s 210s
48. S. Vaughan, J.I. Coward, and R.C. Bast Jr. et al. Rethinking ovarian cancer: recommendations for improving outcomes Nat Rev Cancer 11 2011 719 725
49. C.W. Drescher, C. Shah, and J. Thorpe et al. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule J Clin Oncol 31 2013 387 392
50. L. Valentin, L. Ameye, and A. Testa et al. Ultrasound characteristics of different types of adnexal malignancies Gynecol Oncol 102 2006 41 48
51. A.C. Fleischer, A. Lyshchik, and R.F. Andreotti et al. Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with microbubbles AJR Am J Roentgenol 194 2010 343 348
52. N. Deshpande, Y. Ren, and K. Foygel et al. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging Radiology 258 2011 804 811
53. J.N. McAlpine, S. El Hallani, and S.F. Lam et al. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection Gynecol Oncol 120 2011 385 392
54. H. Song, S.J. Ramus, and J. Tyrer et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 Nat Genet 41 2009 996 1000
55. P.D. Pharoah, Y.Y. Tsai, and S.J. Ramus et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer Nat Genet 45 2013 362 370 [370e361-362]
56. J. Permuth-Wey, K. Lawrenson, and H.C. Shen et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 Nat Commun 4 2013 1627
57. S.E. Bojesen, K.A. Pooley, and S.E. Johnatty et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer Nat Genet 45 2013 371 384 [384e371-372]
58. E.L. Goode, G. Chenevix-Trench, and H. Song et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 Nat Genet 42 2010 874 879
59. S.A. Gayther Inherited risk of ovarian cancer and the implications for screening Int J Gynecol Cancer 22 Suppl. 1 2012 S12 S15
60. P.D. Pharoah, A.C. Antoniou, D.F. Easton, and B.A. Ponder Polygenes, risk prediction, and targeted prevention of breast cancer N Engl J Med 358 2008 2796 2803
61. C.L. Pearce, M.A. Rossing, and A.W. Lee et al. Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer Cancer Epidemiol Biomarkers Prev 22 2013 880 890
62. H. Burton, S. Chowdhury, and T. Dent et al. Public health implications from COGS and potential for risk stratification and screening Nat Genet 45 2013 349 351